{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 333D
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2017)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M017
(2016)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
US Previously Marketed
Source:
INFLUENZA A (H5N1) VIRUS MONOVALENT VACCINE, ADJUVANTED by ID BIOMEDICAL CORPORATION QUEBEC
(2013)
Source URL:
First approved in 2013
Source:
INFLUENZA A (H5N1) VIRUS MONOVALENT VACCINE, ADJUVANTED by ID BIOMEDICAL CORPORATION QUEBEC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(6)(iv) cough/cold:bronchodilator euphorbia pilulifera
Source URL:
First approved in 2013
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
PiGe ll Real Skin Mask Pack by Osung Co., Ltd
(2013)
Source URL:
First approved in 2013
Source:
PiGe ll Real Skin Mask Pack by Osung Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2013
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M019
(2024)
Source URL:
First approved in 2013
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
